Unicycive Therapeutics Inc Ordinary Shares UNCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
-
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
-
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
-
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
-
Unicycive Shares Plunge After FDA Again Rejects Oxylanthanum Carbonate
-
Unicycive Shares Slide Premarket as FDA Rejects Oxylanthanum Carbonate Application
-
Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application
Trading Information
- Previous Close Price
- $5.26
- Day Range
- $5.06–5.36
- 52-Week Range
- $3.71–8.74
- Bid/Ask
- $5.23 / $5.38
- Shares Outstanding
- 27.39M
- Market Cap
- $142.72M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 22
- Website
- https://www.unicycive.com
Valuation
|
Metric
|
UNCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.63 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
UNCY
|
|---|---|
Quick Ratio | 2.06 |
Current Ratio | 2.40 |
Interest Coverage | −746.78 |
Quick Ratio
UNCY
Profitability
|
Metric
|
UNCY
|
|---|---|
Return on Assets (Normalized) | −58.56% |
Return on Equity (Normalized) | −97.72% |
Return on Invested Capital (Normalized) | −99.83% |
Return on Assets
UNCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|kSZJZ@ | LOCK|V@x!J | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|hm@rd! | LOCK|f?t& | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&NN%VnQ | LOCK|>T! | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|nw@T?sV | LOCK|%WR% | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GYHQ??v | LOCK|vY | $36B | |||
| Moderna Inc
MRNA
| LOCK|HXDxn@ | LOCK|pt? | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x!QJY@^? | LOCK|?LLz | $25B | |||
| Incyte Corp
INCY
| LOCK|%Th&&n | LOCK|qb> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|LFkqq&^ | LOCK|l$y | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|TB%jFds | LOCK|Wg | $17B |
United States